CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 86 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $512,430 | +52.7% | 18,600 | 0.0% | 0.10% | +41.9% |
| Q2 2023 | $335,544 | -1.4% | 18,600 | 0.0% | 0.07% | -42.6% |
| Q4 2022 | $340,380 | -3.6% | 18,600 | 0.0% | 0.13% | +50.0% |
| Q3 2022 | $353,000 | +0.6% | 18,600 | 0.0% | 0.09% | +11.7% |
| Q2 2022 | $351,000 | -14.0% | 18,600 | 0.0% | 0.08% | -2.5% |
| Q1 2022 | $408,000 | -22.0% | 18,600 | 0.0% | 0.08% | -12.2% |
| Q4 2021 | $523,000 | +42.1% | 18,600 | 0.0% | 0.09% | +34.3% |
| Q3 2021 | $368,000 | -5.2% | 18,600 | 0.0% | 0.07% | -10.7% |
| Q2 2021 | $388,000 | +26.8% | 18,600 | 0.0% | 0.08% | +15.4% |
| Q1 2021 | $306,000 | +16.3% | 18,600 | 0.0% | 0.06% | +8.3% |
| Q4 2020 | $263,000 | -15.4% | 18,600 | 0.0% | 0.06% | -29.4% |
| Q3 2020 | $311,000 | – | 18,600 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |